Purpose: The development of Clostridium difficile infection after cystectomy is associated with significant morbidity and mortality. We implemented a prospective screening program to identify asymptomatic carriers of C. difficile and assessed its impact on clinical C. difficile infection rates compared to historical matched controls. Materials and Methods: Prospective C. difficile screening prior to cystectomy began in March 2015. The 380 consecutive patients who underwent cystectomy before the initiation of screening (control cohort) were matched based on 5 clinical factors with the 386 patients who underwent cystectomy from March 2015 to December 2017 (trial cohort). Patients who screened positive were placed in contact isolation and treated prophylactically with metronidazole. Multivariable models were built on an intent to screen basis and an effectiveness of screening basis to determine whether screening reduced the rate of symptomatic C. difficile infection postoperatively. Results: With the implementation of the screening protocol the C. difficile infection rate declined from 9.4% to 5.5% (OR 0.52, p ¼ 0.0268) in patients on the intent to screen protocol and from 9.2% to 4.9% in those on the effectiveness of screening protocol (OR 0.46, p ¼ 0.0174). Conclusions: C. difficile screening prior to cystectomy is associated with a significant decrease in the rate of clinically symptomatic infection postoperatively. These results should be confirmed in a randomized controlled trial.
A new strain of CD was discovered in North America in 2005 which showed greater toxicity and was associated with poor outcomes. 4, 9 Of these infected patients 12.5% experienced a severe outcome, defined as intensive care unit admission, colectomy or death, with older patients more likely to experience a severe outcome. Mortality in patients with these toxic strains ranges from 5.4% in those 61 to 70 years old and rises with each decade of life to 14.7% in patients older than 90 years. 9 Recent studies also suggest that asymptomatic carriers of CD can transmit to others and, therefore, contribute to an increased rate of CDI in a hospital setting, particularly when patient rooms are not easily isolated. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
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Patients treated with cystectomy are at higher risk for CDI than the general patient population due to increased age, underlying comorbidities and recent antibiotic exposure with published rates of CDI in patients with cystectomy ranging from 1.4% to 14%.
16e21 It has been demonstrated that the development of CDI after cystectomy is associated with a 2.5-fold increase in mortality and it adds approximately $22,634 in cost per hospitalization per patient.
17 At our institution the CDI incidence from 2010 to 2013 was closer to the high end of this range as reported in 2015. 19 To our knowledge the incidence of asymptomatic CD carriage is unfortunately unknown in patients who undergo cystectomy.
Screening asymptomatic patients for CD is discouraged by the IDSA and the CDC but recent studies suggest a benefit in high risk populations. 22e25 We implemented a prospective screening program prior to cystectomy to address our high incidence of CDI despite adoption of the IDSA and CDC recommendations for isolating and treating symptomatic patients with CDI. We hypothesized that preoperative screening in patients who undergo cystectomy would decrease our institutional incidence of CDI by allowing us to isolate and treat CD carriers prior to the transmission or the development of CDI.
METHODS

Study Cohorts
A total of 765 consecutive patients underwent simple or radical cystectomy at our institution between June 2012 and December 2017. This sample included a cohort of 379 patients who underwent cystectomy between June 2012 and February 2015 prior to the initiation of the screening trial (control cohort) and 386 patients who underwent cystectomy from March 2015 to December 2017 after the initiation of the prospective screening for CD trial (trial cohort). The trial and control cohorts were then matched based on 5 demographic and clinical factors, including age within 5 years, cancer, preoperative antacid use (a proton pump inhibitor or a histamine2 channel antagonist), prolonged antibiotic use (more than 24 hours perioperatively) and receipt of neoadjuvant chemotherapy. Each patient in the trial cohort was matched to at least 1 patient in the control cohort based on matching criteria and vice versa for each patient in the control cohort.
The matched sample consisted of 720 patients, including 358 in the trial cohort and 362 in the control cohort. Of the patients in the trial cohort 283 had screening results for CD (trial screened) and 75 had insufficient screening results (trial unscreened) for CD due to laboratory errors or refusal.
We defined the intent to screen cohort as the 358 patients in the trial cohort and the 362 in the control cohort. Effectiveness in the screening cohort was defined as 258 patients in the trial who were screened and 437 who were unscreened. The unscreened group included 362 controls and 75 trial patients without screening results. All of our subsequent analyses were based on those 2 cohorts.
Screening
Preoperative screening for CD in cystectomy cases began in March 2015. Screening consisted of rectal examination immediately prior to cystectomy with the patient under general anesthesia. Stool samples were collected and sent to the laboratory, where a CD PCR assay was run. Our laboratory PCR assay tests for the gene responsible for toxin B of CD. If stool was not obtained during the digital rectal examination, a swab of rectal mucus was used for analysis. Carriers of CD (screened positive individuals) were placed in isolation rooms with appropriate contact precautions. Carriers were also treated with intravenous metronidazole (500 mg 3 times daily) until the return of bowel function, defined as passage of flatus. Carrier negative patients were otherwise treated on a standardized clinical pathway which has been in existence since 2012 with little change ( fig. 1 ).
Primary Outcomes
The primary outcome was the incidence of postoperative CDI, defined as 3 or more diarrhea episodes per day associated with a positive CD assay within 30 days of the operation. Demographic and clinical factors were collected prospectively on all patients as part of quality improvement measures into an Institutional Review Board approved departmental database. The study received Institutional Review Board approval (IRB No. 1405135110).
Statistical Analysis
Patient demographic and clinical characteristics were reported and compared between the screened trial cohort of 283 patients, the unscreened trial cohort of 75 and the control cohort of 362. ANOVA and the Kruskal-Wallis test were used to compare normally and nonnormally distributed continuous variables, respectively. Categorical variables were compared by the chi-square test. Logistic regression models were fit to examine the cohort difference in postoperative CDI in the intent to screen and the effectiveness of screening cohorts. As covariates all models included known risk factors for CDI, ie age, cancer, antibiotic use, antacid use and chemotherapy. All analysis was completed at a 2-tailed significance level of p ¼ 0.05 using SASÒ, version 9.4. Figure 2 shows a flow chart defining the patient population as well as the rate of CDI in each cohort. Table 1 summarizes patient demographic and clinical characteristics by cohort. Overall the groups were well matched. There was a significant difference in antacid use prior to cystectomy among the cohorts. Compared with the control cohort the patients in the trial cohort were more likely to be on antacids prior to cystectomy (30.1% vs 19.1%, p 0.0001). The method of urinary reconstruction differed among the 3 groups (p ¼ 0.0026). The trial unscreened population was more likely to undergo noncontinent diversion than the other cohorts (63.6% in trial screened cohort vs 74.7% in trial unscreened cohort vs 63.4% in controls).
RESULTS
Baseline Demographics and Clinical Characteristics
C. difficile Analyses
Intent to Screen. The rate of postoperative CDI was 9.4% in the control cohort and 5.5% in the trial cohort. The absolute risk reduction was 3.9% with a number needed to screen of 26 patients to prevent 1 postoperative CDI. After adjusting for patient age, cancer status, prolonged antibiotic use, antacid use and the status of receiving neoadjuvant chemotherapy, the intent to screen led to a 48% reduction in the odds of CDI (OR 0.52, 95% CI 0.29-0.93, p ¼ 0.0268, table 2).
Effect of Screening. About 21% of patients in the trial cohort did not have screening results (trial unscreened) due to an inadequate laboratory stool specimen. The rate of CDI was similar in the control cohort and the trial unscreened cohort (9.4 vs 8.0%, p ¼ 0.7870). The rate of CDI was 4.9% in the trial screened cohort and 9.2% in the unscreened cohort with the latter comprising the combined control cohort and the trial unscreened cohort. The absolute risk reduction was 4.3% with a number needed to screen of 24 patients to prevent 1 postoperative CDI. After adjusting for patient age, cancer status, prolonged antibiotic use, antacid use and the status of receiving neoadjuvant chemotherapy the protective effect of screening demonstrated a 54% reduction in the odds on postoperative CDI (OR 0.46, 95% CI 0.24-0.87, p ¼ 0.0174, table 2).
Adverse Events
No adverse events were identified due to screening or to treating patients who screened positive with a short course of antibiotics. No patients experienced an acute reaction or an allergy to metronidazole. Specifically only 1 patient experienced ileus and 1 required readmission and received metronidazole.
Postoperative complications did not differ among the groups (table 1) 
DISCUSSION
After screening for CD was implemented the incidence of CDI at our institution decreased substantially in patients undergoing cystectomy. When controlling for demographic and clinical factors, screening as well as the intent to screen had a protective effect on developing CDI. None of the other clinical covariates predicted developing CDI. Of the patients 52 (18.4%) screened positive for CD as asymptomatic carriers. Screened positive patients received a short course (mean 3 days) of metronidazole postoperatively. The overall use of antibiotics was low, given the short duration of use and the low percent of asymptomatic carriers. The incidence of CDI at our institution prior to implementing the screening trial was 9.4%. Thus, we would have anticipated that CDI would have developed in 34 patients during the subsequent 2 years if screening had not been initiated. Instead CDI developed in only 20 patients. We treated 52 patients with a short course of metronidazole to prevent treating 14 with a protracted course of metronidazole and/or vancomycin, and prevent the associated potential morbidity and mortality of postoperative CDI. The limitation of morbidity and mortality secondary to postoperative CDI must be stressed. Three of the 54 patients in whom CDI developed died postoperatively and 2 of these deaths were clearly attributable to CDI. All deaths occurred in unscreened patients.
We hypothesized that the lower incidence of CDI in the trial cohort was due to 2 main interventions. 1) Asymptomatic carriers of CD were placed in single occupancy rooms under contact isolation with stricter hand washing policies. The separation of carriers likely reduced the transmission of CD from carriers to noncarriers. This hypothesis is supported by the 4.6% reduction in the CDI incidence between the control and trial cohort members who screened negative.
Results of recent studies support our hypothesis. Genome sequencing was performed in 1,223 patients diagnosed with CDI in the United Kingdom.
26
Of the cases 45% had significant genetic diversity, indicating that the infection originated from a source other than symptomatic cases. The investigators concluded that transmission likely occurred from asymptomatic carriers of CD. Another group evaluated 3,006 patients who were screened for CD during a 5-month period. 11 Molecular subtyping determined that 29% of active CDI cases were genetically associated with asymptomatic carriers in the same hospital. In a smaller study of 634 patients 84% of nosocomial CDI were preceded by documented admission of the strain to the ward by an asymptomatic carrier. 16 Plausible mechanisms of transmission include contamination of the environment and caregiver hands. 13, 27 These studies support the hypothesis that asymptomatic carriers of CD can transmit CD to others and contribute to an increased CDI rate in hospitals. Our data suggest that isolating asymptomatic carriers of CD may decrease symptomatic CDI in hospital units, presumably by reduced transmission.
2) Precautionary treatment with metronidazole likely reduced the rate of symptomatic infection in carriers of CD. Colonization with CD was found to be an independent risk factor for symptomatic infections in patients admitted to the intensive care unit. 25 By prophylactically treating colonized patients we found a 3.6% reduction in CDI incidence between the control cohort and the trial cohort members who screened positive. Antibiotic administration in carriers of CD is controversial and not supported by the ACG (American College of Gastroenterology). This recommendation is based on an older study which focused on eliminating asymptomatic carriage of CD. 28 This was not our intent as we sought to reduce symptomatic CDI in a high risk cohort.
A recent quasi-experimental study evaluated the role of isolation without prophylactic antibiotic treatment of asymptomatic carriers on the incidence of CDI. Carriers of CD in this trial were placed on contact isolation precautions until discharge home. Compared to the pre-intervention control period, the incidence of CDI was drastically reduced after screening (3.9/10,000 vs 6.0/10,000 patient-days). This group concluded that screening and isolating carriers of CD was associated with a lower rate of hospital acquired CDI. 24 Our results would appear to corroborate these findings. Future studies will need to assess the impact of isolation and prophylactic treatment to determine the optimal intervention strategy.
The results of our study should be considered in the context of several limitations. Our trial represents an observational quality improvement project in which the rate of CDI in a screened population was compared with the rate in a control population. Further multi-institutional and randomized investigations are needed to confirm our findings. However, our results give sufficient proof of concept to justify the design and performance of these more laborious and costly evaluations.
We fully acknowledge that we present an observation of a clinical change in practice at our institution. The quasi-experimental pre-post design is limited in the ability to assess changes in CDI rates with time which may have been due to global institutional interventions. However, no other obvious changes in practice aside from the screening protocol explain the lower rates of CDI. All patients were treated by the same urologists and admitted to the same floor of the hospital throughout the period of analysis. To support this the rate of CDI during the study period on the urology ward declined by 38% compared to the control period, which exceeded the 32% CDI rate reduction in the entire hospital. CDI rates on other floors, including medical and colorectal surgical wards, demonstrated a less pronounced rate of CDI reduction ranging from 5% to 33%.
The generalizability of our results may be limited due to the higher incidence rate of CDI compared to that at other institutions.
16e19 However, CDI rates are rising and recent reports suggest that CDI rates in patients who undergo cystectomy may be even higher at other institutions. 5, 20 Moreover, multiple agencies (the ACG, the IDSA and the CDC) have produced guidelines against screening for CD in the general population. 22, 23 Our results directly contradict these statements and suggest that screening in patients at high risk requires further attention.
Lastly, recent reports suggest that isolating asymptomatic carriers alone substantially lowers the CDI rate. 24 Further evaluation is needed on the necessity of prophylactic antibiotic administration and isolation vs isolation of only asymptomatic carriers.
These limitations notwithstanding, we believe that our data are compelling enough to warrant future formal study of this subject. To our knowledge this is the first report investigating the role of screening for CD in patients who undergo cystectomy. This patient population is at high risk for CDI due to a multitude of patient and disease related risk factors. Screening reduced the risk of CDI by 46% to 54%. Our prospective, low risk screening program demonstrated significant promise in reducing morbidity and mortality secondary to CDI in patients undergoing cystectomy.
CONCLUSIONS
Implementing a screening protocol in patients who undergo cystectomy was associated with a significantly decreased incidence of CDI. Although these data are observational, we believe that they are compelling. Further study in the form of randomized trials is warranted to confirm our findings. 
EDITORIAL COMMENTS
CDI after radical cystectomy contributes significantly to patient morbidity, mortality and health care costs. In the United States an estimated $6.3 billion and 2.4 million days of inpatient stay are attributed to CDIs annually. 1 In an effort to prevent symptomatic CDI after cystectomy Calaway et al implemented a preoperative screening protocol in which all CD carriers were placed on isolation and treated with 500 mg metronidazole intravenously 3 times daily until the return of bowel function (flatus), in addition to receiving routine perioperative antibiotics. In this study they found a statistically significant decrease in symptomatic CDI rates from approximately 9% to 5%.
The principle behind treating asymptomatic CD carriers is twofold: preventing symptomatic infection and horizontal transmission. However, guidelines from the CDC recommend against screening and treating asymptomatic patients for CDI while also calling for the careful use of antibiotics (reference 22 in article).
Confirmatory trials are needed to validate the findings of this study and identify the optimal regimen for preoperative screening and perioperative antimicrobial prophylaxis in patients undergoing radical cystectomy. If put into practice, screening patients for CD in combination with judicious antibiotic stewardship may aid in decreasing the morbidity, mortality and health care costs associated with radical cystectomy.
